stockrow
Saturday 7 November 2026
Export NXTC’s income statement to Excel — free account
NextCure, Inc.
NXTC Healthcare Biotechnology
- EPS
- +75.2%
- Free cash flow
- +57.2%
Quarter to June 2026, against a year earlier
5.30
0.18
+3.52%
Follow NXTC
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(116.91%) | (111.23%) | (132.40%) | (195.22%) | |
| (89.28%) | (85.23%) | (104.01%) | (121.60%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(229.45%) | (153.19%) | (196.35%) | (265.10%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(18.29) | (17.45) | (9.54) | (6.97) | |
Free Cash Flow |
(48.94) | (49.61) | (49.98) | (36.98) | |
| Other line items | |||||
Cash ROIC |
(92.77%) | (64.63%) | (88.53%) | (114.73%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.84 | 0.89 | 0.91 | 0.87 | |
Depreciation/Fixed assets |
0.49 | 0.52 | 0.51 | 4.45 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(18.29) | (17.45) | (9.54) | (6.97) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026